HRSA Reporting on Services Funded Through Program Income
On October 29th, HRSA issued a notice that Ryan White Clinics will be required to report client-level data on patients whose services are funded through program income, starting with the…
HAB Revises Policy on Allowable Uses of Ryan White Grant Funds
On October 22, HAB revised its Policy Clarification Notice (PCN) 16-02, Ryan White HIV/AIDS Program Services: Eligible Individuals & Allowable Uses of Funds, which was originally released in 2016. PCN…
Proposed Rule Would Require Drug Manufacturers to Disclose Prices in TV Advertisements
On Monday, Health and Human Services Secretary Alex Azar announced a proposed rule that would require pharmaceutical manufacturers to disclose wholesale acquisition cost (“WAC”) prices in direct-to-consumer TV advertisements for…
Gilead Will Begin Marketing Lower Cost Hepatitis C Drugs in January
Gilead Sciences Inc. announced that it would begin selling generic versions of the company’s two leading treatments for hepatitis C at substantially reduced prices. The generic versions of Epclusa and…
E&C Health Subcommittee Reviews 340B Program and Recent GAO Report on Contract Pharmacies
The House Energy and Commerce (E&C) Health Subcommittee held a hearing on the 340B program yesterday at 10 a.m. titled “Opportunities to Improve the 340B Drug Pricing Program.” The Subcommittee received testimony…
Senate HELP Drug Pricing Hearing, 340B Not Addressed
The 340B program was not a focus of today’s Senate HELP hearing on President Trump’s drug pricing blueprint entitled “American Patients First: The Trump Administration Blueprint to Lower Drug Prices…
Senate HELP Committee to Hold Third 340B Hearing on June 19
The Senate Committee on Health, Education, Labor and Pensions (HELP) will hold a third hearing on the 340B program on June 19, 2018 at 10 a.m, Eastern time. The hearing…
Senate HELP Hearing “Perspectives on the 340B Drug Discount Program” Scheduled March 15
The Senate Committee on Health, Education, Labor and Pensions (HELP), which has Senate jurisdiction over the 340B program, will hold a hearing titled “Perspectives on the 340B Drug Discount Program”…
340B Legislation Introduced
On Thursday, December 21st, Rep. Larry Bucshon (R-IN) and Rep. Scott Peters (D-CA) introduced the 340B PAUSE Act, H.R. 4710, in the U.S. House of Representatives. The bill would “amend…
NIH Director Says March-In Rights Cannot Be Used to Lower Drug Prices
National Institutes of Health (NIH) Director Francis Collins stated yesterday that the agency does not have the authority to use its “march-in” rights as a tool to lower drug prices. …